Toshitaka Manda

1.7k total citations
53 papers, 1.5k citations indexed

About

Toshitaka Manda is a scholar working on Molecular Biology, Cancer Research and Organic Chemistry. According to data from OpenAlex, Toshitaka Manda has authored 53 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Molecular Biology, 9 papers in Cancer Research and 7 papers in Organic Chemistry. Recurrent topics in Toshitaka Manda's work include Cancer therapeutics and mechanisms (7 papers), Neuropeptides and Animal Physiology (5 papers) and Cancer, Hypoxia, and Metabolism (5 papers). Toshitaka Manda is often cited by papers focused on Cancer therapeutics and mechanisms (7 papers), Neuropeptides and Animal Physiology (5 papers) and Cancer, Hypoxia, and Metabolism (5 papers). Toshitaka Manda collaborates with scholars based in Japan and United States. Toshitaka Manda's co-authors include Kyoichi Shimomura, Sanae Matsumoto, Fusako Nishigaki, Ikuo Kawamura, Sueo Mukumoto, Yoshinori Naoe, Seitaro Mutoh, Jo Mori, Masahiko Matsuo and Susumu Tsujimoto and has published in prestigious journals such as International Journal of Cancer, Biochemical Pharmacology and Life Sciences.

In The Last Decade

Toshitaka Manda

53 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Toshitaka Manda Japan 21 1.0k 252 247 183 168 53 1.5k
James P. Thomas United States 17 781 0.8× 143 0.6× 350 1.4× 234 1.3× 120 0.7× 30 1.6k
Ronald L. Merriman United States 17 767 0.8× 186 0.7× 224 0.9× 118 0.6× 70 0.4× 35 1.2k
Allan S. Wagman United States 17 1.4k 1.4× 447 1.8× 285 1.2× 217 1.2× 196 1.2× 28 2.2k
Baskaran Govindarajan United States 21 1000 1.0× 210 0.8× 412 1.7× 221 1.2× 276 1.6× 26 1.8k
Sébastien Sauvage Belgium 15 1.0k 1.0× 247 1.0× 171 0.7× 118 0.6× 166 1.0× 20 1.5k
Benjamin Le Calvé Belgium 20 818 0.8× 345 1.4× 264 1.1× 229 1.3× 159 0.9× 31 1.6k
Eugenia M. Yazlovitskaya United States 25 1.2k 1.2× 126 0.5× 423 1.7× 278 1.5× 120 0.7× 48 1.9k
John H. Hutchinson United States 26 882 0.9× 654 2.6× 147 0.6× 70 0.4× 146 0.9× 90 1.9k
Xianzhi Mao United States 11 884 0.9× 109 0.4× 206 0.8× 234 1.3× 123 0.7× 16 1.2k
Sanae Matsumoto Japan 17 887 0.9× 220 0.9× 152 0.6× 61 0.3× 62 0.4× 34 1.3k

Countries citing papers authored by Toshitaka Manda

Since Specialization
Citations

This map shows the geographic impact of Toshitaka Manda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Toshitaka Manda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Toshitaka Manda more than expected).

Fields of papers citing papers by Toshitaka Manda

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Toshitaka Manda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Toshitaka Manda. The network helps show where Toshitaka Manda may publish in the future.

Co-authorship network of co-authors of Toshitaka Manda

This figure shows the co-authorship network connecting the top 25 collaborators of Toshitaka Manda. A scholar is included among the top collaborators of Toshitaka Manda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Toshitaka Manda. Toshitaka Manda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sasakawa, Yuka, Yoshinori Naoe, Takeshi Inoue, et al.. (2004). Marker genes to predict sensitivity to FK228, a histone deacetylase inhibitor. Biochemical Pharmacology. 69(4). 603–616. 46 indexed citations
2.
Sasakawa, Yuka, Yoshinori Naoe, Takeshi Inoue, et al.. (2003). Effects of FK228, a novel histone deacetylase inhibitor, on tumor growth and expression of p21 and c-myc genes in vivo. Cancer Letters. 195(2). 161–168. 37 indexed citations
3.
Sasakawa, Yuka, Yoshinori Naoe, Takahisa Noto, et al.. (2003). Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors. Biochemical Pharmacology. 66(6). 897–906. 67 indexed citations
4.
Maeda, Yasue, et al.. (2002). Resiniferatoxin antagonizes cisplatin-induced emesis in dogs and ferrets. European Journal of Pharmacology. 442(3). 273–278. 22 indexed citations
5.
Inami, Masamichi, Ikuo Kawamura, Susumu Tsujimoto, et al.. (2002). Effects of FK317, a novel anti-cancer agent, on survival of mice bearing B16BL6 melanoma and Lewis lung carcinoma. Cancer Letters. 181(1). 39–45. 15 indexed citations
6.
Sasakawa, Yuka, Yoshinori Naoe, Takeshi Inoue, et al.. (2002). Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo. Biochemical Pharmacology. 64(7). 1079–1090. 90 indexed citations
7.
Kawamura, Ikuo, Ryuichi Morishita, Naohiro Tomita, et al.. (1999). Intratumoral injection of oligonucleotides to the NFκB binding site inhibits cachexia in a mouse tumor model. Gene Therapy. 6(1). 91–97. 102 indexed citations
8.
Tsuji, Kiyoshi, et al.. (1998). Synthesis and effects of novel thiazole derivatives against thrombocytopenia. Bioorganic & Medicinal Chemistry Letters. 8(18). 2473–2478. 6 indexed citations
9.
Naoe, Yoshinori, Masamichi Inami, Ikuo Kawamura, et al.. (1998). Cytotoxic Mechanisms of FK317, a New Class of Bioreductive Agent with Potent Antitumor Activity. Japanese Journal of Cancer Research. 89(6). 666–672. 22 indexed citations
10.
Ogino, Takashi, Kiyoshi Tsuji, Takashi Tojo, et al.. (1998). Discovery of FR115092 : A novel antinephritic agent. Bioorganic & Medicinal Chemistry Letters. 8(1). 75–80. 6 indexed citations
11.
Naoe, Yoshinori, Masamichi Inami, Sanae Matsumoto, et al.. (1998). Different Effects of FK317 on Multidrug‐resistant Tumor in vivo and in vitro. Japanese Journal of Cancer Research. 89(10). 1047–1054. 16 indexed citations
12.
Naoe, Yoshinori, Masamichi Inami, Sanae Matsumoto, et al.. (1998). FK317, a Novel Substituted Dihydrobenzoxazine, Exhibits Potent Antitumor Activity against Human Tumor Xenografts in Nude Mice. Japanese Journal of Cancer Research. 89(12). 1306–1317. 21 indexed citations
13.
Naoe, Yoshinori, Masamichi Inami, Fusako Nishigaki, et al.. (1998). FK317: a novel substituted dihydrobenzoxazine with potent antitumor activity which does not induce vascular leak syndrome. Cancer Chemotherapy and Pharmacology. 42(1). 31–36. 38 indexed citations
14.
Nakajima, Hidenori, Yasuhiro Hori, Hiroshi Terano, et al.. (1996). New Antitumor Substances, FR901463, FR901464 and FR901465. II. Activities against Experimental Tumors in Mice and Mechanism of Action.. The Journal of Antibiotics. 49(12). 1204–1211. 186 indexed citations
15.
Kawamura, Ikuo, Elizabeth P. Lacey, Fusako Nishigaki, et al.. (1995). A New Aromatase Inhibitor, FR901537. II. Pharmacological and Antitumor Effects.. The Journal of Antibiotics. 48(8). 763–767. 2 indexed citations
16.
Kawamura, Ikuo, Elizabeth P. Lacey, Yoshio Tanaka, et al.. (1993). The Estrogenic and Antiestrogenic Activities of Droloxifene in Human Breast Cancers. The Japanese Journal of Pharmacology. 63(1). 27–34. 9 indexed citations
17.
Manda, Toshitaka, et al.. (1990). The efficacy of combined treatment with recombinant human tumor necrosis factor-α and 5-fluorouracil is dependent on the development of capillaries in tumor. European Journal of Cancer and Clinical Oncology. 26(2). 93–99. 11 indexed citations
18.
Kawamura, Ikuo, Sueo Mukumoto, Toshitaka Manda, et al.. (1989). Antiestrogenic and antitumor effects of droloxifene in experimental breast carcinoma.. PubMed. 39(8). 889–93. 13 indexed citations
19.
Nakamura, Takaaki, et al.. (1989). Effect of FK973, a new antitumor antibiotic, on the cell cycle of L1210 cells in vitro.. The Japanese Journal of Pharmacology. 49(3). 317–324. 26 indexed citations
20.
Shimomura, Kyoichi, et al.. (1988). Recombinant human tumor necrosis factor‐α: Thrombus formation is a cause of anti‐tumor activity. International Journal of Cancer. 41(2). 243–247. 98 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by James P. Thomas Breakdown of academic impact, for papers by Ronald L. Merriman Breakdown of academic impact, for papers by Allan S. Wagman Breakdown of academic impact, for papers by Baskaran Govindarajan Breakdown of academic impact, for papers by Sébastien Sauvage Breakdown of academic impact, for papers by Benjamin Le Calvé Breakdown of academic impact, for papers by Eugenia M. Yazlovitskaya Breakdown of academic impact, for papers by John H. Hutchinson Breakdown of academic impact, for papers by Xianzhi Mao Breakdown of academic impact, for papers by Sanae Matsumoto
Rankless by CCL
2026